Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The drug has changed the face of obesity treatment
EMA, 2024)
[11] In April 2026 the sponsor announced that SYNCHRONIZE-1 a double-blind, placebo-controlled study of roughly 725 adults with obesity or overweight without diabetes met its co-primary endpoints, reporting mean bodyweight loss of about 16.6% at 76 weeks versus about 3.2% on placebo, with a large proportion of participants achieving at least 5% weight loss
The decision to choose a specific medication should be made after a thorough discussion with healthcare professionals, taking into consideration the unique health profiles and goals of each patient
US$ 26.28
US$ 28.22
US$ 27.22
US$ 28.57
US$ 24.81
US$ 20.09
US$ 26.24
